Iqvia vs Maxcyte: revenue, profit, margins and growth compared
Iqvia brought in $16.3B of revenue in fiscal 2025, Maxcyte $33M in fiscal 2025. Revenue changed by +5.9% at Iqvia and -14.5% at Maxcyte on the year before, so Iqvia grew faster. Iqvia kept 8.3% of its revenue as net profit, Maxcyte -135.1%. Free cash flow was $2.1B at Iqvia and -$36.2M at Maxcyte.
Fiscal years as each company reports them; the two may end in different months.
Questions about Iqvia and Maxcyte
Which is bigger by revenue, Iqvia or Maxcyte?
Iqvia is bigger by revenue: $16.3B in fiscal 2025, against $33M for Maxcyte in fiscal 2025.
Which keeps more of its revenue as profit, Iqvia or Maxcyte?
Iqvia had a net margin of 8.3% in fiscal 2025; Maxcyte had -135.1% in fiscal 2025.
Which grew revenue faster, Iqvia or Maxcyte?
In their latest fiscal years revenue changed by +5.9% at Iqvia and -14.5% at Maxcyte.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.